

**A Retrospective study of L-asparaginase induced
Thrombosis in Pediatric Acute Lymphoblastic
Leukemia Patients**

Thesis submitted for fulfillment of Master Degree in Pediatric Oncology

Submitted

By

Omar Shawki Farid Arafah

MB.B.Ch, Cairo University

Under supervision

Of

Prof. Dr. Iman Abd El-Mokhaless Sidhom

Professor of Pediatric Oncology

National Cancer Institute, Cairo University

Prof. Dr. Iman Mohamed Zaki

Professor of Radiodiagnosis

National Cancer Institute, Cairo University

Dr. Ahmad Mohamed Kamel

Lecturer of Pediatric Oncology

National Cancer Institute, Cairo University

Cairo University

2009

Acknowledgment

In the name of Allah, most gracious, most merciful.

All praise and glory to Allah the almighty who alone made this small objective accomplished. I feel honored and privileged to glorify his name in the sincerest way through this small accomplishment and ask him to accept my efforts.

My deep appreciation goes to my thesis advisor Prof. Dr. Iman Abd El-Mokhales Sidhom, the professor of Pediatric Oncology, National Cancer Institute, Cairo University, for her constant help, guidance and countless hours of attention she devoted throughout the course of this work.. Her priceless suggestions made this work interesting and learning for me.

I am especially thankful and grateful for my thesis committee member Prof. Dr. Iman Mohamed Zaki, the professor of Radiodiagnosis, National Cancer Institute, Cairo University, for her guidance and support in understanding and interpretation of the radiological data.

Thanks also due to my thesis committee Dr. Ahmad Mohamed Kamel, lecturer of Pediatric Oncology, National Cancer Institute, Cairo University for his useful comments on my research and review of the thesis.

Special thanks for Prof. Dr. Inas EL- Attar, the professor of Statistics, for her generous support and patience to process and analyze the study population data.

I also offer my regards and blessings to all my colleagues and friends who supported me in any respect during the completion of the work. I take this opportunity to thank Children Cancer Hospital in Egypt, for permission to use and access the hospital database and offering all needed support to finish this work.

I wish to express my heartfelt gratitude to my parents for their encouragement, prayers and continuous support. I owe a lot of thanks for my dear wife, children and sisters for their extra patience and motivation.

Omar Arafah.

List of contents

• Abstract.....	1
• Introduction and Aim of the work.....	2
• Review of Literature:	
1. Acute Lymphoblastic leukemia	
> Epidemiology of ALL.....	6
> Aetiology.....	9
> Clinical presentation.....	16
> MRD techniques.....	23
> Prognostic Factors.....	27
> Therapy.....	37
> Adverse effects.....	46
2. Malignancy and Thrombosis:	
> Epidemiology and prevalence.....	50
> Prothrombotic risk factors.....	53
> Pathogenesis.....	63
> Primary prophylaxis.....	67
> Direct thrombin inhibitors, FFP and AT.....	68
> Investigation and management.....	70
3. Asparaginase Coagulopathy:	
> Historical background and preparations.....	76
> Anti-asparaginase Antibodies.....	87
> Effect of different preparation	91
> Pathogenesis.....	94
> Prevalence.....	98
> L-ASP induced PRES.....	104
> Risk factors.....	107
> Management.....	109
> Antidote and side effects.....	122
> Mortality and Morbidity.....	123
• Patients and Methods.....	126
• Results.....	144
• Discussion.....	176
• Conclusions.....	193
• Recommendations.....	195
• English Summary.....	197
• References.....	199
• Appendix.....	223
• Arabic summary.....	257

List of Tables

Table 1	Management Strategies for Thromboembolisms
Table 2	Remission Induction
Table 3	Continuation treatment (120 weeks for girls and 146 weeks for boys)
Table 4	Reinduction phases in total XV protocol of ALL
Table 5	Continuation treatment of total XV protocol
Table 6	Cause relations and location of the 26 Coagulopathy events among studied pediatric ALL patients
Table 7	Asparaginase coagulopathy type and time of occurrence among the studied pediatric ALL patients
Table 8	Clinical presentations of L-asparaginase related coagulopathy among studied pediatric ALL patients
Table 9	L-asparaginases related mortality among studied pediatric ALL patients
Table 10	Characteristics of L-asparaginase related mortality in study population
Table 11	Anticoagulant therapy in Lasparaginase related coagulopathy among studied pediatric ALL patients
Table 12	Duration of anticoagulant therapy in Lasparaginase related coagulopathy among studied pediatric ALL patients
Table 13	Total dosage and number of ASP received in the protocol in relation to risk stratification
Table 14	Dosage and number of ASP received in relation to risk stratification in negative and positive patients
Table 15	Dexamethasone Dosage (mg) in relation to risk stratification in all studied patients
Table 16	Incidence of l-asparaginase related coagulopathy in relation to age groups among studied pediatric ALL patients

List of Tables

Table 17	Effect of age in SR/HR patient's protocol
Table 18	Incidence of l-asparaginase related coagulopathy in relation to gender among studied pediatric ALL patients
Table 19	Incidence of l-asparaginase related coagulopathy in relation to initial TLC among studied pediatric ALL patients
Table 20	Incidence of l-asparaginase related coagulopathy in relation to two initial TLC groups among studied pediatric ALL patients
Table 21	Incidence of l-asparaginase related coagulopathy in relation to Immunophenotyping among studied pediatric ALL patients
Table 22	Incidence of l-asparaginase related coagulopathy in relation to DNA Index among studied pediatric ALL patients
Table 23	Incidence of l-asparaginase related coagulopathy in relation to molecular translocation among studied pediatric B-lineage ALL patients
Table 24	Incidence of l-asparaginase related coagulopathy in relation to Risk stratification among studied pediatric ALL patients
Table 25	Effect of risk stratification in patients with ages within 1-10 years
Table 26	Multivariate analysis of age and risk stratification as independent factors for thromboembolism
Table 27	Prognostic factors affecting overall survival
Table 28	Cox proportional hazard models of the effect of prognostic factors on overall survival
Table 29	Prognostic factors affecting event free survival
Table 30	Cox proportional hazard models of the effect of prognostic factors on event free survival

List of Figures

- Figure 1** A model illustrating the events required to produce overt leukaemia in childhood
- Figure 2** Management of central venous line (CVL)-related thrombosis. LMWH, low molecular weight heparin; deep vein thrombosis; MRV, magnetic resonance venography
- Figure 3** Incidence of coagulopathy in the studied 416 pediatric ALL patients
- Figure 4** Cause relation of Coagulopathy events among the studied pediatric ALL patients
- Figure 5** Causes of Coagulopathy events not related to L-asparaginase among the studied pediatric ALL patients
- Figure 6** Location of the 20 Coagulopathy events related to L-asparaginase among studied pediatric ALL patients
- Figure 7** Type of asparaginase coagulopathies that occurred among the studied pediatric ALL patients
- Figure 8** Timing of asparaginase coagulopathy events that occurred among the studied pediatric ALL patients
- Figure 9** Clinical presentations of L- asparaginase related coagulopathy among studied pediatric ALL patients
- Figure 10** L- asparaginase related mortality among studied pediatric ALL patients
- Figure 11** CT brain of a patient with L-asparaginase induced haemorrhage at the time of the event and during follow up
- Figure 12** CT brain of a patient with L-asparaginase induced haemorrhagic infarction at the time of the event and during follow up
- Figure 13** Initial and follow up MRV of patients having L-asparaginase induced venous thrombosis
- Figure 14** MRI of a patient with L-asparaginase induced ischemia at the time of event and during follow up

List of Figures

- Figure 15** Incidence of l-asparaginase related coagulopathy In relation to age groups among studied pediatric ALL patients
- Figure 16** Incidence of l-asparaginase related coagulopathy in relation to gender among studied pediatric ALL patients
- Figure 17** Incidence of l-asparaginase related coagulopathy in relation to TLC among studied pediatric ALL patients
- Figure 18** Incidence of l-asparaginase related coagulopathy in relation to Immunophenotyping among studied pediatric ALL patients
- Figure 19** incidence of l-asparaginase related coagulopathy in relation to DNA Index among studied pediatric ALL patients
- Figure 20** Molecular translocations in patients positive for l-asparaginase related coagulopathy among studied pediatric B-lineage ALL patients
- Figure 21** L-asparaginase related coagulopathy in relation to Risk Stratification among studied pediatric ALL patients
- Figure 22** Disease Free Survival of the studied 416 pediatric ALL patients
- Figure 23** Event Free Survival of the studied 416 pediatric ALL patients
- Figure 24** Overall Survival of the studied 416 pediatric ALL patients
- Figure 25** Disease free survival among positive and negative patients
- Figure 26** Event free survival among positive and negative patients
- Figure 27** Overall survival among positive and negative patients

List of Abbreviations

6MP: 6- mercaptopurine

ACCP: The current American College of chest physicians

ADC: Apparent diffusion coefficient

ALL: Acute lymphoblastic leukemia

AML: Acute myeloid leukemia

AMP 21: Intrachromosomal amplification of AML 1 gene on chromosome 21

ANC: Absolute neutrophilic count

AP: Acute Pancreatitis

Ara-C: Cytosine Arabinoside

BCP phenotype: B cell precursor phenotype

BCSH: British Committee for Standards in Haematology

BFM: Berlin– Frankfurt–Munster

C.ALL: Common Acute lymphoblastic leukemia

CCSG: Children cancer study group

CD: Cluster of differentiation

CNS: Central nervous system

COG: Children Oncology Group

CR: Complete remission

CSF: Cerebrospinal fluid

CTX: Cyclophosphamide

DDI: Double delayed intensification

DFCI: Dana-Farber consortium

DFS: Disease free survival

Dox: Doxorubicin

DTI: Direct Thrombin inhibitors

DWI: Diffusion weighted images

EFS: Event free survival

EMF: Electromagnetic field

ETGC: Endogenous thrombin generation capacity

FAB: French-American-British

FDA: Food & Drug Administration

FFP: Fresh frozen plasma

FISH: Fluorescence in situ hybridization

GST: Glutathione S transferase

HC II: Heparin cofactor II

HCT: Hematopoietic cell transplantation

HDMTX: High dose methotrexate

HIT: Heparin induced thrombocytopenia

HIV: Human immunodeficiency virus

HLA: Human leukocyte antigen

IgG: Immunoglobulin heavy chain

IL6: Interleukin 6

INR: International ratio

IPT: Immunophenotyping

IT: Intrathecal

IU: International Unit

L-ASP: L-asparaginase

LMWH: low molecular weight heparin

m TOR: mammalian target of Rapamycin

MLL: Mixed lineage leukemia gene

MRD: Minimal residual disease

List of Abbreviations

MRI: Magnetic resonance imaging

MRV: Magnetic resonance venography

MTHFR: Methyl Tetrahydrofolate reductase

MTX: Methotrexate

NHL: Non Hodgkin lymphoma

OAT: Oral Anti-coagulant therapy

OS: overall survival

P value: Probability value

PAI-1: Plasminogen activator inhibitor 1

PARP: poly ADP ribose- polymerase

PCA: Procoagulant activity

PE: Pulmonary embolism

PEG –ASP: Poly ethylene glycol asparagines

POG: Pediatric Oncology Group

PRES: Posterior reversible encephalopathy syndrome

PROTEKT: PROphylaxis of ThromboEmbolism in Kids trial

PT: Prothrombin time

PTT: Partial Thromboplastin time

REVIVE: Reviparin in childhood venous thromboembolism

SAS: Statistical Analysis system

SHBG: Sex hormone binding globulin

SJCRH: San Jude Cancer Research Hospital

SR: Standard risk HR: High risk LR: Low risk

TAT: Thrombin-Antithrombin complex

TBG: Thyroxine binding globulin

TCR: T cell receptor

TE: Thromboembolism

List of Abbreviations

TH: T helper

TLC: Total leukocytic count

TNF α : Tumor necrosis factor Alpha

t-PA: Tissue plasminogen Activator

UFH: Unfractionated heparin

UKCCS: United Kingdom Childhood Cancer Study

VCR : Vincristine

VKA: Vitamin K antagonist

vWF: Von Willebrand factor

WBCs: White blood cell count

Abstract

Background: Thromboembolism (TE) is a well-recognized serious complication in association with ALL leading to significant morbidity. Development of TE does interfere with the scheduled treatment plan for ALL and, thus, ultimate outcome from ALL. Concomitant administration of asparaginase and steroids is likely to be associated with higher incidence of TE, especially in children with at least one prothrombotic risk factor.

Aim: To study the incidence and outcome of asparaginase related coagulopathy and to assess biological, laboratory and clinical parameters affecting thromboembolic risk.

Methods: A retrospective study of 416 pediatric ALL patients who were treated at the Children's Cancer Hospital in Egypt (CCHH) during the time period between 7th of July 2007 and end of July 2009 and followed till end of May 2010. They received ALL protocol adopted from SJCRH study XV for low and standard/high risk.

Results: Twenty patients (4.8%) had coagulopathy related to L-asparaginase. CNS affection occurred in 12 patients (60%), DVT in neck and lower limbs in 8 patients (40%). The Majority of patients had thrombosis (55%), followed by cerebral haemorrhage (20%), cerebral thrombosis combined with haemorrhagic infarction (15%), cerebral Ischemia (5%) and cerebral infarction (5%). Seven patients (35%) occurred during induction, 3 (15%) post induction and 10 (50%) during maintenance. Four cases died as a complication to L-ASP induced coagulopathy events, all of them had CNS affection.

The total dosage of L-ASP and Dexamethazone were significantly higher in SR/HR than LR protocol. It was found that age, and risk stratification significantly increased the risk of L-ASP coagulopathy and only age retained its significance on multivariate analysis. Event free and overall survival were adversely affected in L-ASP positive patients, while disease free survival was not. Risk stratification and L-ASP coagulopathies were the only factors that independently affected event free survival and overall survival.

Conclusion: It can be concluded that combination of L-ASP and steroids increased the risk of coagulopathy in ALL pediatric patients especially in older ages, higher risk and higher doses of L-ASP. Mortality related to TE events affected outcome of patients.

Keywords: *Acute lymphoblastic leukemia, Asparaginase, Thromboembolism, Haemorrhage.*

Introduction and Aim of the work

L-asparaginase is a hydrolase that catalyzes the conversion of L-asparagine; an endogenous amino acid necessary for the function of some neoplastic cells, such as lymphoblasts. In most human cells, deficiency of L-asparagine can be compensated by alternative synthesis pathway through which L-asparagine is produced from aspartic acid and glutamine by asparagine synthetase. Depletion of L-asparagine from plasma by L-asparaginase results in inhibition of RNA and DNA synthesis with the subsequent blastic cell apoptosis.

Owing to the unique anti-cancer mechanism of action, L-asparaginase has been introduced to the multi-drug chemotherapy in children with acute lymphoblastic leukemia, which has contributed to significant improvement of therapy outcomes and to achieve complete remission in about 90% of patients.

Despite its high therapeutic efficacy, L-asparaginase can increase the risk of thrombosis. Inhibition of protein synthesis causes most complications observed during treatment with a native and pegylated form of L-asparaginase, including impaired functions of liver, kidneys or central nervous system. Thrombotic events occur as a result of inhibited synthesis of anticoagulant proteins (mainly antithrombin). [\(Piatkowska-Jakubas et al., 2008\)](#)

The occurrence of Thromboembolism (TE) seems to be emerging from the interaction of the disease, the therapy and possible genetic predisposition for hypercoagulability, especially in children with ALL. Antileukemic therapy influences the haemostatic system either by direct effect of the chemotherapeutic agents or indirectly through the effect of supportive care, e.g. central venous line (CVL) or infectious complications secondary to immunosuppression [\(Uma et al., 2003\)](#)

Asparaginase and steroids are shown to induce hypercoagulable state by suppression of natural anticoagulants, especially AT and plasminogen, and by elevations in F VIII/vWF complex, respectively. In addition, steroid therapy causes hypofibrinolytic state by dose-dependent increase in plasminogen activator inhibitor 1 (PAI-1) levels.

Introduction and Aim of the Work

Combination of these effects coupled with increased thrombin generation may be responsible for the increased incidence of TE observed with concomitant administration of asparaginase and steroids ([Athale et al., 2003](#)).

The reported incidence of TE in childhood ALL varies from 1.1% to 36.7% with an overall average of 3.2% ([Mitchell et al., 2003](#)) The wide variation in the reported incidence of TE seems to be related to the definition of TE (symptomatic versus asymptomatic), diagnostic methods used for detection of TE, study design (prospective versus retrospective analysis), and ALL treatment protocols. The studies designed to evaluate patients for asymptomatic TE (e.g. central venous line (CVL) related TE) have reported much higher incidence of TE compared to studies reporting only symptomatic TE.

Studies published prior to 1990 seem to report lower incidence of TE compared to more recent studies. The overall incidence of TE on studies conducted or reported prior to year 1990 is 1.8% (range, 1.1–14.2%) ([Priest et al., 1982](#)) ; whereas the same for studies or reports after 1990 is 4.7% (range, 1.7–36.7%) ([Mitchell et al., 2003](#)). Thus, it seems that incidence of TE has either increased over time or the apparent increase is related to the improved methods for detection.

Majority of thromboembolisms are venous and 5.0% of patients were reported to have multiple sites involved. Mitchell et al., reported CNS-TE in 65% and DVT in 16% of patients ([Mitchell et al., 1995](#)). In contrast, ([Athale et al., 2003](#)) reported a much higher prevalence of DVT (43%)

Most of the Thrombotic complications occur during the induction phase of therapy. Lower doses of asparaginase (ASP) for long periods were associated with the highest incidence of thrombosis, as were anthracyclines and prednisone (instead of dexamethasone). The presence of central lines and of thrombophilic genetic abnormalities also appeared to be frequently associated with thrombosis ([Appel et al., 2008](#)).

The morbidity is usually reported for patients with CNS-TE. Approximately 15–20% of patients with CNS-TE are reported to have residual neurological deficits in the form of hemiparesis, aphasia or seizure disorder ([Ott et al., 1988](#)).

Introduction and Aim of the Work

The overall mortality from TE in patients with ALL varies from 0 to 4.8%. However, amongst patients who develop TE, the case fatality ratio, based on individual series, could be 0–50%, with an average of 15%. With all cause mortality in children with ALL being approximately 15%, TE may be an important cause of mortality in children with ALL. Pulmonary embolism and CNS-TE are collectively responsible for majority of all TE-related deaths. An overall mortality related to CNS-TE is 21.1% ([Kankirawatana et al., 2002](#)).

During L-Asparaginase treatment the 11- to 16-year-old showed lower values in procoagulant and, even more, in anticoagulant factor levels compared to the younger children. Decreased synthesis of alpha2-antiplasmin and plasminogen during L-Asparaginase treatment resulted in less potential of clot lysis by plasmin in children older than 11 years of age. In conclusion, a more severe decline of anticoagulant and fibrinolytic parameters in children between 11 and 16 years of age underline that these children are at higher risk of thrombosis during ALL induction treatment ([Nowak-Göttl et al., 2002](#)). Age related risk may partly reflect the effect of ALL-risk stratification. Higher dose steroids combined with ASP may lead to an increased risk of TE in HR patients.

Management and prevention of venous thromboembolism (VTE) in cancer patients is challenging. Not only is the risk of VTE in cancer patients elevated compared to patients without malignancies, but also is standard treatment based on Vitamin K antagonists (VKAs) less effective and associated with an increased frequency of major bleeding.

Therapy with Low Molecular Weight Heparin (LMWH) is less sensitive to drug interactions, not hindered by a narrow therapeutic window and needs no monitoring. LMWH therapy therefore seems more practical and may also be more effective in cancer patients. Moreover a possible survival benefit has been suggested, the underlying mechanism of which is not yet unraveled ([Ten Cate-Hoek et al., 2008](#)).

For the long term treatment of venous thromboembolism in patients with cancer, LMWH compared to vitamin K antagonists reduces venous thromboembolism but not death ([Akl et al., 2008](#)).

Fresh frozen plasma administration for the prevention and treatment of acquired ATIII deficiency secondary to ASP has no demonstrable benefit on plasma levels of